AI-native translational medicine

From discovery
to decision.

AionWell helps oncology teams weigh early evidence and decide which study to fund next.

Featured engagement

Translational
Evidence Sprint

A focused, four-to-six-week review of one development decision.

Explore the sprint

Our approach

Which study should come next?

Follow one early oncology question from the first observation to a funding decision.

Illustrative antibody program

Two studies. One budget decision.

An early antibody program has activity in a selected tumor model. Before the next review, the team can commission a tissue study or a distribution study. Which uncertainty matters more to its choice of indication?

Decision record

Decision
Tissue expression or antibody distribution
Known
Activity in a selected preclinical model
Missing
Relevance to the intended patient population

Illustrative antibody program

Match the study to the uncertainty.

A tissue study can examine variation in target expression. Imaging can examine where a labeled antibody accumulates. Each addresses a different reason the animal finding might fail to translate.

Decision record

Tissue study
Which samples express the target?
Imaging study
Where does the labeled molecule accumulate?
Shared limit
Clinical benefit remains an open question

Illustrative antibody program

Write down what would change the plan.

In this example, uncertainty about the population drives the decision. The team prioritizes an independent tissue set and reserves imaging for a later delivery question. The brief records when to revisit that choice.

Decision record

Prioritize
Review target expression in an independent set
Defer
A new distribution study
Revisit if
Delivery becomes the main uncertainty

Project inquiries

What decision is your team facing?

Discuss a project